EA201991729A1 - ANTIBODIES TO TGF-BETA AND THEIR APPLICATION - Google Patents

ANTIBODIES TO TGF-BETA AND THEIR APPLICATION

Info

Publication number
EA201991729A1
EA201991729A1 EA201991729A EA201991729A EA201991729A1 EA 201991729 A1 EA201991729 A1 EA 201991729A1 EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A1 EA201991729 A1 EA 201991729A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tgf
antibodies
beta
application
antibody
Prior art date
Application number
EA201991729A
Other languages
Russian (ru)
Inventor
Гари Шапиро
Кевин Брауэн
Патрик ФИНН
Ричард С. Грегори
Рао Кодури
Фэн Лю
Наталья Малкова
Парминдер Манку
Джек Р. Поллард
Хуавэй Цю
Йоахим Тайльхабер
Кристофер Винтер
Марчелла Юй
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201991729A1 publication Critical patent/EA201991729A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

В настоящем изобретении предусмотрено улучшенное панспецифичное антитело к TGF-β для лечения состояний, опосредованных TGF-β, в том числе аутоиммунных заболеваний, фиброзных состояний и форм рака. Также предусмотрены способы и пути применения антитела в сочетании с другими иммуномодулирующими средствами, такими как антитело к PD-1.The present invention provides an improved pan-specific antibody to TGF-β for the treatment of conditions mediated by TGF-β, including autoimmune diseases, fibrotic conditions and forms of cancer. Also provided are methods and routes for using the antibody in combination with other immunomodulatory agents, such as an anti-PD-1 antibody.

EA201991729A 2017-01-20 2018-01-19 ANTIBODIES TO TGF-BETA AND THEIR APPLICATION EA201991729A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305061 2017-01-20
PCT/IB2018/000088 WO2018134681A1 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use

Publications (1)

Publication Number Publication Date
EA201991729A1 true EA201991729A1 (en) 2019-12-30

Family

ID=58018036

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991729A EA201991729A1 (en) 2017-01-20 2018-01-19 ANTIBODIES TO TGF-BETA AND THEIR APPLICATION

Country Status (3)

Country Link
EP (1) EP3571227A1 (en)
EA (1) EA201991729A1 (en)
WO (1) WO2018134681A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
KR20210030411A (en) 2018-07-10 2021-03-17 사노피 Combination therapy for cancer targeting CD38 and TGF-beta
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
US20230057012A1 (en) 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304979A (en) * 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525362A (en) 2003-04-30 2006-11-09 ジェンザイム コーポレーション Combination of TGF-β antagonist and renin-angiotensin-aldosterone antagonist for treating renal dysfunction
AU2006213875B2 (en) 2005-02-08 2010-08-19 Genzyme Corporation Antibodies to TGFBETA
KR101970025B1 (en) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Antibodies and other molecules that bind b7-h1 and pd-1
DK3312195T3 (en) * 2013-03-20 2020-01-06 Genzyme Corp METHODS OF TREATING IMPERFECTA OF OSTEOGENESIS
PL3702373T3 (en) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
MX2017004810A (en) * 2014-10-14 2017-10-16 Novartis Ag Antibody molecules to pd-l1 and uses thereof.
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
JP6901400B2 (en) * 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド Cancer treatment using TGF-β and PD-1 inhibitors

Also Published As

Publication number Publication date
WO2018134681A8 (en) 2019-10-10
EP3571227A1 (en) 2019-11-27
WO2018134681A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
EA201991729A1 (en) ANTIBODIES TO TGF-BETA AND THEIR APPLICATION
EA202092410A1 (en) CONJUGATES OF CAMPTOTHETCIN WITH PEPTIDE
EA201891732A1 (en) BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR
MD3303379T2 (en) Tigit-binding agents and uses thereof
EA201891983A8 (en) COMBINED THERAPY BY ANTIBODIES TO CD73
EA201990208A1 (en) CHIMER ANTIGENIC RECEPTORS AIMED AT BCMA AND WAYS OF THEIR APPLICATION
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
EA201891992A1 (en) CHIMERIC RECEPTORS AND WAYS OF THEIR APPLICATION
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
MX2019005426A (en) Anti-lag3 antibodies and antigen-binding fragments.
EA201790288A1 (en) ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, PHARMACEUTICAL COMPOSITION AND APPLICATION
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201890443A1 (en) BISPECIFIC MONOVALENT DIATELS, ABLE TO CONNECT B7-H3 AND CD3 AND THEIR APPLICATION
PE20161390A1 (en) MULTI-SPECIFIC ANTIBODIES
MX2023002588A (en) Anti-tgf-beta antibodies and their use.
EA201692539A1 (en) ANTIBODIES AND ANTIGENS-BINDING FRAGMENTS, WHICH SPECIFICALLY CONNECT WITH THE PROUCH OF TAU ASSOCIATED WITH MICROTUBULES
EA202190609A1 (en) ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G
EA201791590A1 (en) ANTIBODIES TO TAU AND THEIR APPLICATION
EA201691541A1 (en) NEW ANTI-BAFF ANTIBODIES
EA202091130A1 (en) LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN
EA202191785A1 (en) ANTIBODIES TO CTLA4 AND METHODS OF THEIR APPLICATION
EA201992460A1 (en) BTLA ANTIBODY ANTIBODIES AND THEIR APPLICATION
EA201691521A1 (en) ANTIBODIES TO INTERLEUKIN-21
EA201792561A1 (en) ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION